Ocular Therapeutix (OCUL) Reports Q1 Loss, Misses Revenue Estimates

Ocular Therapeutix (OCUL) came out with a quarterly loss of $0.37 per share versus the Zacks Consensus Estimate of a loss of$ 0.29. This compares to loss of $0.24 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -27.59%. A quarter ago, it was expected that this biotechnology company would post a loss of$ 0.24 per share when it actually produced a loss of $0.29, delivering a surprise of -20.83%.Over the last four quarters, the c ...